Stay updated on Lenvatinib and Pembrolizumab in DTC Clinical Trial
Sign up to get notified when there's something new on the Lenvatinib and Pembrolizumab in DTC Clinical Trial page.

Latest updates to the Lenvatinib and Pembrolizumab in DTC Clinical Trial page
- Check3 days agoChange DetectedThe page’s release/version indicator was updated from “Revision: v3.5.2” to “Revision: v3.5.3.” This reflects a change in the ClinicalTrials.gov page revision, not the underlying study information.SummaryDifference0.0%

- Check10 days agoChange DetectedPage revision updated from v3.5.0 to v3.5.2.SummaryDifference0.0%

- Check17 days agoNo Change Detected
- Check24 days agoChange DetectedAdded Hurthle cell carcinoma of thyroid and differentiated thyroid carcinoma to the conditions, and included a Resources section with the Genetic and Rare Diseases Information Center.SummaryDifference0.2%

- Check39 days agoChange DetectedRevision updated from v3.4.3 to v3.5.0. No user-facing content or functionality is affected.SummaryDifference0.0%

- Check46 days agoChange DetectedRevision updated from v3.4.2 to v3.4.3. This appears to be a metadata version change and does not modify core content such as study details or eligibility criteria.SummaryDifference0.0%

- Check74 days agoChange DetectedSite footer updated to Revision: v3.4.2; the government funding-lapse notice and the older Revision: v3.4.1 label were removed.SummaryDifference0.4%

Stay in the know with updates to Lenvatinib and Pembrolizumab in DTC Clinical Trial
Enter your email address, and we'll notify you when there's something new on the Lenvatinib and Pembrolizumab in DTC Clinical Trial page.